QQQ   264.09 (-0.03%)
AAPL   108.03 (+0.85%)
MSFT   202.22 (+0.81%)
FB   248.90 (-0.05%)
GOOGL   1,421.60 (+0.87%)
AMZN   3,019.80 (+0.66%)
NVDA   493.94 (+1.85%)
TSLA   369.01 (-2.98%)
BABA   269.35 (-1.32%)
CGC   14.28 (-2.19%)
GE   6.02 (-1.47%)
MU   49.57 (-0.56%)
AMD   76.15 (+1.90%)
T   27.79 (-0.29%)
F   6.52 (-1.81%)
ACB   5.06 (-2.13%)
GILD   62.40 (-1.09%)
NFLX   470.00 (-0.13%)
DIS   122.17 (-0.90%)
BAC   23.08 (-0.77%)
BA   147.43 (-2.48%)
QQQ   264.09 (-0.03%)
AAPL   108.03 (+0.85%)
MSFT   202.22 (+0.81%)
FB   248.90 (-0.05%)
GOOGL   1,421.60 (+0.87%)
AMZN   3,019.80 (+0.66%)
NVDA   493.94 (+1.85%)
TSLA   369.01 (-2.98%)
BABA   269.35 (-1.32%)
CGC   14.28 (-2.19%)
GE   6.02 (-1.47%)
MU   49.57 (-0.56%)
AMD   76.15 (+1.90%)
T   27.79 (-0.29%)
F   6.52 (-1.81%)
ACB   5.06 (-2.13%)
GILD   62.40 (-1.09%)
NFLX   470.00 (-0.13%)
DIS   122.17 (-0.90%)
BAC   23.08 (-0.77%)
BA   147.43 (-2.48%)
QQQ   264.09 (-0.03%)
AAPL   108.03 (+0.85%)
MSFT   202.22 (+0.81%)
FB   248.90 (-0.05%)
GOOGL   1,421.60 (+0.87%)
AMZN   3,019.80 (+0.66%)
NVDA   493.94 (+1.85%)
TSLA   369.01 (-2.98%)
BABA   269.35 (-1.32%)
CGC   14.28 (-2.19%)
GE   6.02 (-1.47%)
MU   49.57 (-0.56%)
AMD   76.15 (+1.90%)
T   27.79 (-0.29%)
F   6.52 (-1.81%)
ACB   5.06 (-2.13%)
GILD   62.40 (-1.09%)
NFLX   470.00 (-0.13%)
DIS   122.17 (-0.90%)
BAC   23.08 (-0.77%)
BA   147.43 (-2.48%)
QQQ   264.09 (-0.03%)
AAPL   108.03 (+0.85%)
MSFT   202.22 (+0.81%)
FB   248.90 (-0.05%)
GOOGL   1,421.60 (+0.87%)
AMZN   3,019.80 (+0.66%)
NVDA   493.94 (+1.85%)
TSLA   369.01 (-2.98%)
BABA   269.35 (-1.32%)
CGC   14.28 (-2.19%)
GE   6.02 (-1.47%)
MU   49.57 (-0.56%)
AMD   76.15 (+1.90%)
T   27.79 (-0.29%)
F   6.52 (-1.81%)
ACB   5.06 (-2.13%)
GILD   62.40 (-1.09%)
NFLX   470.00 (-0.13%)
DIS   122.17 (-0.90%)
BAC   23.08 (-0.77%)
BA   147.43 (-2.48%)
Log in
NASDAQ:AUTL

Autolus Therapeutics Stock Forecast, Price & News

$12.36
-0.33 (-2.60 %)
(As of 09/24/2020 09:53 AM ET)
Add
Compare
Today's Range
$12.36
Now: $12.36
$12.43
50-Day Range
$12.36
MA: $14.58
$16.17
52-Week Range
$3.00
Now: $12.36
$17.19
Volume200 shs
Average Volume78,767 shs
Market Capitalization$555.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.96
Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma. It is also developing AUTO4, a programmed T cell therapy that is in Phase I/II clinical trial for the treatment of peripheral T-cell lymphoma; and AUTO6, a programmed T cell therapy for treating neuroblastoma. Autolus Therapeutics plc has a collaboration partnership with AbCellera Biologics Inc. on antibody discovery project. The company was founded in 2014 and is headquartered in London, the United Kingdom.
Read More
Autolus Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AUTL
CUSIPN/A
CIKN/A
Phone44-20-3829-6230

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.91 million
Book Value$5.67 per share

Profitability

Net Income$-123,850,000.00
Net Margins-10,518.19%

Miscellaneous

EmployeesN/A
Market Cap$555.95 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
$12.36
-0.33 (-2.60 %)
(As of 09/24/2020 09:53 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

How has Autolus Therapeutics' stock price been impacted by Coronavirus?

Autolus Therapeutics' stock was trading at $6.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AUTL shares have increased by 82.6% and is now trading at $12.36.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Autolus Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Autolus Therapeutics
.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Autolus Therapeutics
.

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics Ltd - (NASDAQ:AUTL) issued its earnings results on Thursday, August, 6th. The company reported ($0.62) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.71) by $0.09. Autolus Therapeutics had a negative return on equity of 48.60% and a negative net margin of 10,518.19%.
View Autolus Therapeutics' earnings history
.

What price target have analysts set for AUTL?

7 analysts have issued 1-year price targets for Autolus Therapeutics' shares. Their forecasts range from $24.00 to $38.00. On average, they expect Autolus Therapeutics' share price to reach $27.33 in the next year. This suggests a possible upside of 121.1% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
.

Who are some of Autolus Therapeutics' key competitors?

What other stocks do shareholders of Autolus Therapeutics own?

Who are Autolus Therapeutics' key executives?

Autolus Therapeutics' management team includes the following people:
  • Dr. Christian Martin Itin, Chairman & CEO (Age 55)
  • Dr. Martin Pulé, Founder, Sr. VP & Chief Scientific Officer (Age 47)
  • Mr. Andrew J. Oakley, CFO & Sr. VP (Age 57)
  • Mr. Christopher Vann, Sr. VP & COO (Age 55)
  • Mr. Matthias Alder, Sr. VP, Chief Bus. Officer, Gen. Counsel & Sec. (Age 54)

When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an IPO on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Artal Group S.A. (0.89%), Alyeska Investment Group L.P. (0.60%), FMR LLC (0.20%), FMR LLC (0.20%), Opaleye Management Inc. (0.13%) and Trexquant Investment LP (0.10%).

Which institutional investors are selling Autolus Therapeutics stock?

AUTL stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, FMR LLC, FMR LLC, Artal Group S.A., Alyeska Investment Group L.P., Tudor Investment Corp Et Al, Goldman Sachs Group Inc., and Advisor Group Holdings Inc..

Which institutional investors are buying Autolus Therapeutics stock?

AUTL stock was bought by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Trexquant Investment LP, California Public Employees Retirement System, Jane Street Group LLC, New York State Common Retirement Fund, and UBS Group AG.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $12.36.

How big of a company is Autolus Therapeutics?

Autolus Therapeutics has a market capitalization of $555.95 million and generates $2.91 million in revenue each year. The company earns $-123,850,000.00 in net income (profit) each year or ($2.88) on an earnings per share basis.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 44-20-3829-6230 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.